References of "Tassin, Françoise"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailRecurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy
DARCIS, Gilles ULiege; Van der Auwera, Gert; GIOT, Jean-Baptiste ULiege et al

in BMC Infectious Diseases (2017), 17

Background: Leishmaniasis is a protozoan disease caused by parasites of the genus Leishmania, transmitted to humans by sandflies. The diagnosis of leishmaniasis is often challenging as it mimics many ... [more ▼]

Background: Leishmaniasis is a protozoan disease caused by parasites of the genus Leishmania, transmitted to humans by sandflies. The diagnosis of leishmaniasis is often challenging as it mimics many other infectious or alignant diseases. The disease can present in three ways: cutaneous, mucocutaneous, or visceral leishmaniasis, which rarely occur together or consecutively. Case presentation: The patient was a 52 years old immunosuppressed Belgian woman with a long history of severe rheumatoid arthritis. She underwent bone marrow biopsy to explore thrombocytopenia. Diagnosis of visceral leishmaniasis was made by identification of Leishman Donovan (LD) bodies in macrophages. Treatment with liposomal amphotericin B was successful. She later developed cutaneous leishmaniasis treated with amphotericin B lipid complex. She next presented with relapsing cutaneous lesions followed by rapidly progressing lymphadenopathies. Biopsy confirmed the diagnosis of leishmaniasis. Treatments by miltefosine, amphotericin B, N-methyl-glucamine antimoniate were subsequently initiated. She later presented a recurrent bone marrow involvement treated with intramuscular paromomycin and miltefosine. She died two years later from leukemia. At the time of death, she presented with a mucosal destruction of the nose. A Leishmania-specific PCR (Polymerase Chain Reaction) identified L. infantum as etiological agent. Conclusions: Clinicians should be aware of the potential concomitant or sequential involvement of multiple anatomic localizations of Leishmania in immunosuppressed patients. [less ▲]

Detailed reference viewed: 20 (0 ULiège)
Full Text
Peer Reviewed
See detailLymphocytoses B monoclonales : de la revue de la littérature à la pratique de laboratoire.
KEUTGENS, Aurore ULiege; Foguenne, Jacques ULiege; Gothot, André ULiege et al

in Annales de biologie clinique (2016), 74(2), 168-175

Monoclonal B-cell lymphocytosis (MBL) is defined as an asymptomatic condition characterized by the presence of less than 5,000 monoclonal B-cells per microliter and the absence of clinical signs or ... [more ▼]

Monoclonal B-cell lymphocytosis (MBL) is defined as an asymptomatic condition characterized by the presence of less than 5,000 monoclonal B-cells per microliter and the absence of clinical signs or symptoms of a B-cell lymphoproliferative disorder. Most MBL cases involve B cells presenting an identical phenotype to CLL (CLL-like MBL) with a Catovsky-Matutes score of 3 to 5 and share the same chromosomal abnormalities than CLL. Depending on the absolute B cell count, one may distinguish low-count CLL-like MBL (<500 B cells/muL) which have no evidence of progression, no reduction in overall survival, no increase in infection risk and do not require any specific follow-up. Patients with clinical CLL-like MBL (>500 B cells/muL) have a 1% to 2% per year risk of progression to CLL requiring therapy, a higher risk of infectious complications and mortality implicating an annual follow-up by hematologist. MBL may also express other less common phenotypes and are named atypical MBL in case of CD5 antigen expression (Catovsky-Matutes score: 1-2) and non-CLL-like MBL for CD5 negative cases (Catovsky-Matutes score: 0-2). Their poorer prognosis implicates imaging studies, bone marrow biopsy and cytogenetic analysis in addition to physical examination in order to rule out non-hodgkinien lymphoma, and require a more frequent follow-up. This review focuses on key concepts in the classification, diagnosis, monitoring and biology of MBL in laboratory practice. [less ▲]

Detailed reference viewed: 50 (13 ULiège)
Full Text
Peer Reviewed
See detailAtypical plasma cells with coexpression of myeloid markers and bundles of Auer rod-like inclusions.
KEUTGENS, Aurore ULiege; FOGUENNE, Jacques ULiege; Gothot, André ULiege et al

in International journal of laboratory hematology (2015), 37(4), 85-6

Detailed reference viewed: 39 (25 ULiège)
Full Text
See detailValidation of paroxysmal nocturnal hemoglobinuria detection by flow cytometry
Louis, Céline; FOGUENNE, Jacques ULiege; KEUTGENS, Aurore ULiege et al

Poster (2014)

Detailed reference viewed: 30 (6 ULiège)
Full Text
See detailDétection de l'hémoglobinurie paroxystique nocturne par cytométrie en flux : Validation
Louis, Céline; FOGUENNE, Jacques ULiege; KEUTGENS, Aurore ULiege et al

in Revue de l'Association Belge des Technologues de Laboratoire = Tijdschrift van de Belgische Vereniging van Laboratoriumtechnologen (2014), 41(3), 240

Detailed reference viewed: 40 (10 ULiège)
Full Text
Peer Reviewed
See detailAnalyse automatisée des liquides de ponction et des liquides céphalorachidiens: Evaluation du Sysmex XE-5000
HO, Thi Thanh Giang ULiege; KEUTGENS, Aurore ULiege; HUWART, Aline ULiege et al

in Immuno-Analyse & Biologie Spécialisée [=IBS] (2011), 26

Le mode d’analyse des liquides de ponction du Sysmex XE-5000 a été évalué sur 159 liquides de ponction, dont 60 liquides céphalorachidiens. La numération érythrocytaire et leucocytaire a été comparée aux ... [more ▼]

Le mode d’analyse des liquides de ponction du Sysmex XE-5000 a été évalué sur 159 liquides de ponction, dont 60 liquides céphalorachidiens. La numération érythrocytaire et leucocytaire a été comparée aux comptages réalisés en microscopie en chambre de Fuchs-Rosenthal. La différentiation des cellules monucléées et polynucléées par le XE-5000 a été comparée à la formule manuelle obtenue sur lames de cytocentrifugation. Une bonne corrélation a été obtenue entre le XE-5000 et la technique manuelle avec des coefficients de corrélation supérieurs à 0,8 pour la numération des érythrocytes et des leucocytes ainsi que pour la différenciation leucocytaire pour la plupart des liquides de ponction. La limite de sensibilité fonctionnelle (c’est-à-dire une précision intra-série supérieure à 20 %) a été atteinte pour des numérations érythrocytaires inférieures à 400/ L et leucocytaires inférieures à 30/ L. La contamination inter-échantillons est négligeable et la linéarité est satisfaisante jusqu’à 400 érythrocytes/ L et 30 leucocytes/ L. Ces résultats montrent que l’analyse automatisée des liquides de ponction par le XE-5000 est une alternative acceptable à la technique microscopique de référence aussi bien pour la numération érythrocytaire et leucocytaire que pour la différenciation des cellules polymorphonucléées et mononucléées pour la majorité des liquides de ponction y compris les liquides céphalorachidiens. The body fluid mode on the Sysmex XE-5000 automated hematology analyzer was evaluated on 99 body fluids and 60 cerebrospinal fluids. Erythrocyte and leukocyte numeration was compared to microscopic counts on Fuchs-Rosenthal chambers. Differentiation of mononuclear (MN) and polymorphonuclear (PMN) cells on the XE-5000 was compared to manual differential on cytospin slides. A good agreement was found between the XE-5000 and the manual method with correlation coefficients more than 0.8 for erythrocyte counts, leukocyte counts and leukocyte differentiation in most types of body fluids. The functional sensitivity limit (i.e., within run precision more than 20%) was reached for red blood cell counts more than 400/ L and white blood cell counts more than 30/ L. Carry over was negligible and linearity was adequate for as low as 400 erythrocytes/ L and 30 leucocytes/ L. Our results demonstrate that the automated body fluid analysis on the XE-5000 is an acceptable alternative to the microscopic reference method for erythrocyte and leukocyte numeration as well as MN and PMN differential for most body fluids including cerebrospinal fluids. [less ▲]

Detailed reference viewed: 155 (19 ULiège)
Full Text
Peer Reviewed
See detailCHIC cells: a novel ALK+ cell line derived from a relapsed anaplastic large cell lymphoma
Thielen, Caroline ULiege; Bisig, Bettina ULiege; Gofflot, Stéphanie ULiege et al

in British Journal of Haematology (2011), 152

Since the initial description of anaplastic large cell lymphoma (ALCL) as a proliferation of large CD30+ lymphoid cells, the morphological spectrum of ALCL positive for anaplastic lymphoma kinase (ALCL ... [more ▼]

Since the initial description of anaplastic large cell lymphoma (ALCL) as a proliferation of large CD30+ lymphoid cells, the morphological spectrum of ALCL positive for anaplastic lymphoma kinase (ALCL, ALK+) has expanded, and beyond the common pattern most frequently encountered, several variants have been identified, including the lymphohistiocytic and the small cell patterns (Swerdlow et al, 2008). Only ten ALK+ ALCL cell lines are currently available, and most were derived from tumours demonstrating the common type morphology (Drexler & MacLeod, 2004). We have established a novel cell line (CHIC) from the cerebrospinal fluid of a 32-year-old man with relapsing/refractory ALK+ ALCL with a t(2;5)(p23;q35) translocation whose initial tumour exhibited lymphohistiocytic features. This cell line is now made available to the scientific community. In addition to multiple in vitro applications, the tumourigenic capacity of these cells represents a useful property for in vivo drug testing. [less ▲]

Detailed reference viewed: 64 (22 ULiège)
Full Text
Peer Reviewed
See detailInositide-specific phospholipase c beta1 gene deletion is a rare event in myelodysplastic syndromes.
Herens, Christian ULiege; Ketelslegers, O.; Tassin, Françoise ULiege et al

in Leukemia (2006), 20(3), 521-2522-3

Detailed reference viewed: 22 (8 ULiège)
Full Text
Peer Reviewed
See detailBack pain and renal failure
Delanaye, Pierre ULiege; Bovy, Christophe ULiege; de Leval, Laurence ULiege et al

in Lancet (2004), 364(9449), 1992

Detailed reference viewed: 49 (14 ULiège)
Full Text
Peer Reviewed
See detailClonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases.
Herens, Christian ULiege; Baron, Frédéric ULiege; Croisiau, Christiane et al

in Cancer Genetics & Cytogenetics (2003), 147(1), 78-80

Imatinib mesylate (tested as STI571), an abl kinase inhibitor, induces sustained, complete hematologic and cytogenetic responses in chronic myelocytic leukemia (CML) patients; however, emergence of clonal ... [more ▼]

Imatinib mesylate (tested as STI571), an abl kinase inhibitor, induces sustained, complete hematologic and cytogenetic responses in chronic myelocytic leukemia (CML) patients; however, emergence of clonal chromosomal aberrations in Philadelphia-negative (Ph-) cells during treatment has been reported. We describe two CML patients in chronic phase who presented with complete cytogenetic responses during imatinib mesylate therapy but developed new clonal chromosomal rearrangements in Ph- cells. The first patient presented with a duplication of chromosome 1, dup(1)(q21q42), and the second showed two new clonal aberrations consisting of inv(1)(q12q32) and del(7)(q22) in the same clone. [less ▲]

Detailed reference viewed: 93 (11 ULiège)
Full Text
Peer Reviewed
See detailCessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia.
Piron, Maude ULiege; Loo, Martine; Gothot, André ULiege et al

in Blood (2001), 97(2), 442-8

Little information is available on the evolution of erythropoiesis after interruption of recombinant human erythropoietin (rHuEpo) therapy. Iron-overloaded rats received 20 daily injections of rHuEpo ... [more ▼]

Little information is available on the evolution of erythropoiesis after interruption of recombinant human erythropoietin (rHuEpo) therapy. Iron-overloaded rats received 20 daily injections of rHuEpo. During treatment, reticulocytes, soluble transferrin receptor (sTfR), and hematocrit increased progressively. This was accompanied by a substantial expansion of spleen erythropoiesis but a decrease in the bone marrow. Five weeks after treatment, rats developed a significant degree of a regenerative anemia. Erythropoietic activity, as assessed by reticulocytes, sTfR, erythroid cellularity, iron incorporation into heme, and the number of erythroid colonies, was severely depressed 3 weeks after cessation of rHuEpo. This was followed by regeneration of erythroblasts and reticulocytes at weeks 6 to 7 post-Epo, but erythroid progenitors recovered only partially by that time. The anemia was definitely corrected 2 months after cessation of rHuEpo treatment. Serum Epo levels remained elevated for several weeks, but the sensitivity of marrow erythroid precursors to Epo was preserved. No rat antibodies to rHuEpo were detected, and serum from post-Epo animals did not exert any inhibitory activity on erythropoiesis. In conclusion, after cessation of intensive rHuEpo therapy, there was a strong inhibition of erythropoietic activity with secondary anemia followed by late recovery. This was not due to antibodies or other soluble inhibitory factors, a defect in endogenous Epo production, or a loss of sensitivity to Epo. This may rather represent intrinsic erythroid marrow exhaustion, mostly at the level of erythroid progenitors but also at later stages of erythropoiesis. [less ▲]

Detailed reference viewed: 49 (7 ULiège)
Full Text
Peer Reviewed
See detailDeletion of the 5'-ABL region: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patients.
Herens, Christian ULiege; Tassin, Françoise ULiege; Lemaire, Véronique ULiege et al

in British Journal of Haematology (2000), 110(1), 214-6

Inclusion of the BCR-ABL ES probe in routine cytogenetics led to the identification of a subgroup of Philadelphia positive (Ph+) chronic myeloid leukaemia patients characterized by a 5'-ABL deletion. This ... [more ▼]

Inclusion of the BCR-ABL ES probe in routine cytogenetics led to the identification of a subgroup of Philadelphia positive (Ph+) chronic myeloid leukaemia patients characterized by a 5'-ABL deletion. This anomaly was observed in 5/51 cases (9.8%). Cytological and clinical data suggest that the 5'-ABL deletion may be associated with dysplastic features of polymorphonuclear cells and metamyelocytes and a short chronic phase duration. [less ▲]

Detailed reference viewed: 44 (6 ULiège)
Peer Reviewed
See detailA four-parameter index of marrow dysplasia has predictive value for survival in myelodysplastic syndromes.
Tassin, Françoise ULiege; Dewé, Walthère ULiege; Schaaf, Nicole ULiege et al

in Leukemia & Lymphoma (2000), 36(5-6), 485-96

Marrow dysplasia is a major characteristic of patients with myelodysplastic syndrome (MDS), along with marrow blastosis, cytopenia and cytogenetic anomalies. However, the impact of the degree of marrow ... [more ▼]

Marrow dysplasia is a major characteristic of patients with myelodysplastic syndrome (MDS), along with marrow blastosis, cytopenia and cytogenetic anomalies. However, the impact of the degree of marrow dysplasia on survival has not been fully assessed. In this retrospective analysis of 111 patients selected according to the IPSS criteria of MDS diagnosis, the presence or absence of 21 dysplasia characteristics recognizable in bone marrow smears stained by the May-Grunwald-Giemsa method was correlated with patient survival. Using Cox proportional hazards regression analysis, megaloblastosis (MEGALO), neutrophil agranularity (AGRAN) and hypogranularity (HYPOGRAN) were highly significant predictors (p < 0.005), and Pelger-Huet anomaly (PELGHUET) a significant predictor (p = 0.05), of patient survival. The regression analysis yielded a dysplasia-based risk index (DI) where DI = 1.26 MEGALO + 0.82 AGRAN - 1.08 HYPOGRAN + 0.45 PELGHUET. The two subgroups of 60 and 47 patients with DI < or = 0 and > 0 showed highly significant differences in median survivals (2.6 vs 1.1 yrs; p <0.0001). Multivariate analysis further showed that DI offered additional predictive power that was independent of that provided by the IPSS (p=0.002 and 0.001 respectively). Analysis of survival curves stratified for IPSS and DI showed that the additional predictive power offered by inclusion of the DI essentially concerned the IPSS low/INT-1 risk categories. Further stratification for age did not improve survival prediction. The data indicate that a set of 4 dysplasia parameters can offer some prediction for survival of MDS patients in addition to that provided by the IPSS. Further multicenter studies should aim at including some form of evaluation of the degree of dysplasia in prognostic systems. [less ▲]

Detailed reference viewed: 60 (9 ULiège)
Full Text
Peer Reviewed
See detailL'image du mois. Purpura thrombocytopenique auto-immun.
Smitz, Simon ULiege; Neven, I.; Sautois, Brieuc ULiege et al

in Revue Médicale de Liège (1999), 54(8), 645

Detailed reference viewed: 6 (0 ULiège)
Full Text
Peer Reviewed
See detailTranslocation (2;3)(p21;q26) as the sole anomaly in a case of primary myelofibrosis.
Herens, Christian ULiege; Hermanne, Jean-Philippe; Tassin, Françoise ULiege et al

in Cancer Genetics & Cytogenetics (1999), 110(1), 62-4

Translocation t(2p;3q) is a rare but recurrent finding in myeloid disorders. We present the first case of primary myelofibrosis with t(2;3)(p21;q26) as the sole chromosomal anomaly. The comparison with ... [more ▼]

Translocation t(2p;3q) is a rare but recurrent finding in myeloid disorders. We present the first case of primary myelofibrosis with t(2;3)(p21;q26) as the sole chromosomal anomaly. The comparison with the 11 other previously published myeloid-associated t(2p;3q) cases confirms that this nonrandom translocation involves a pluripotent stem cell and is associated with a poor prognosis. [less ▲]

Detailed reference viewed: 83 (13 ULiège)
Full Text
Peer Reviewed
See detailLes syndromes myélodysplasiques: syndromes préleucémiques
Tassin, Françoise ULiege; Hermanne, Jean-Philippe; Schaaf-Lafontaine, Nicole ULiege et al

in Revue Médicale de Liège (1998), 53(6), 357-62

The myelodysplastic syndromes (MDS) are a heterogeneous group of disorders characterized by peripheral blood cytopenias with a hypercellular bone marrow exhibiting dyspoiesis. The predominant in elderly ... [more ▼]

The myelodysplastic syndromes (MDS) are a heterogeneous group of disorders characterized by peripheral blood cytopenias with a hypercellular bone marrow exhibiting dyspoiesis. The predominant in elderly patients are associated with a high risk of progression to acute myelogenous leukemia. The etiology of MDS is unknown in most cases. About 10% of MDSs are secondary. MDS are classified by the French American British (FAB) classification into five subgroups. The incidence of the disorders is difficult to estimate but it seems to be increasing. Clonal cytogenetic aberrations are found in 30 to 50% of de novo MDS. The only currative treatment for MDS is allogeneic bone marrow transplantation. [less ▲]

Detailed reference viewed: 152 (13 ULiège)
Peer Reviewed
See detailRétinoïdes et leucémie aigue promyelocytaire. Une révolution thérapeutique
Hermanne, Jean-Philippe; Tassin, Françoise ULiege; Bours, Vincent ULiege et al

in Revue Médicale de Liège (1996), 51(3), 217-23

Detailed reference viewed: 54 (2 ULiège)